Skip to main content
. Author manuscript; available in PMC: 2022 Aug 3.
Published in final edited form as: Ann Oncol. 2020 Nov 21;32(2):229–239. doi: 10.1016/j.annonc.2020.11.007

Fig 5. ctDNA and clinical outcomes.

Fig 5.

A) Overview of the ctDNA detection across different time points [T0: baseline/pretreatment, T1: 3 weeks after initiation of therapy, T2: between two treatment regimens (paclitaxel and AC), T3: after NAC prior to surgery]. The right panel shows a swimmer plot depicting the length of follow-up and events in 75 patients with survival data. The primary endpoint of the study was distant recurrence-free survival. B) Proportion of subtypes according to groups based on pCR and ctDNA status at T3. C) Patient survival stratified based on ctDNA status after NAC (T3) and response to treatment (pathological complete response, pCR). Inset table shows the numbers and percentages of patients according to subtype and response/ctDNA status.